Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

This review article focuses on the research progress made in the structural modifications of
camptothecin (CPT), a potent cytotoxic natural alkaloid. CPT possesses a unique 5-fused …

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …

Serine/threonine kinase, cell division cycle 7 (CDC7) is critical for initiating DNA replication.
TAK-931 is a specific CDC7 inhibitor, which is a next-generation replication stress (RS) …

Simple Summary Since the first antibody–drug conjugate (ADC) was approved in 2000, the
landscape of these targeted drugs has evolved over the years, profoundly changing the …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

HER3 is a unique member of the EGFR family of tyrosine kinases, which is broadly
expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate …

Bystander‐killing payloads can significantly overcome the tumor heterogeneity issue and
enhance the clinical potential of antibody‐drug conjugates (ADC), but the rational design …

Recent advances in targeted therapy and immunotherapy have substantially improved the
treatment of melanoma. However, therapeutic strategies are still needed for unresponsive or …

Abstract Hepato-Pancreato-Biliary (HPB) malignancies constitute a highly aggressive group
of cancers that have a dismal prognosis. Patients not amenable to curative intent surgical …